SCLX, SCLXW · CIK 0001820190 · operating
Scilex Holding Company develops and commercializes non-opioid pain management therapies for acute and chronic pain indications. The company's marketed portfolio includes ZTlido, a prescription lidocaine topical system for postherpetic neuralgia pain; ELYXYB, a ready-to-use oral solution for acute migraine treatment; and GLOPERBA, a liquid colchicine formulation for gout flare prophylaxis. The company maintains development partnerships with Oishi and Itochu for lidocaine tape products and with Lifecore Biomedical for manufacturing services.
The company operates a pipeline of three late-stage candidates. SP-102 (SEMDEXA), a dexamethasone sodium phosphate viscous gel for epidural injection in lumbosacral radicular pain, has completed Phase 3 testing. SP-103, a higher-strength lidocaine formulation targeting chronic neck and low back pain, completed Phase 2 trials. SP-104, a low-dose naltrexone delayed-release capsule for fibromyalgia treatment, has completed Phase 1 evaluation.
Scilex operates as a Delaware-incorporated company headquartered in Palo Alto, California, with approximately 30 full-time employees. The company is traded on Nasdaq with a market capitalization of $0.1 billion as of the most recent data available.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.61 | $-0.56 | +52.3% | |
| 2023 | $-1.28 | $-1.28 | -652.9% | |
| 2022 | $-0.17 | $-0.17 | -440.0% | |
| 2021 | $0.05 | $0.05 | — | |
| 2020 | — | — | — |